Beyond Air (XAIR) to Post Quarterly Earnings on Tuesday

Beyond Air (NASDAQ:XAIR) is expected to announce its Q1 2027 results before the market opens on Tuesday, August 11th. Analysts expect Beyond Air to announce earnings of ($10.10) per share and revenue of $1.8640 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:00 AM ET.

Beyond Air (NASDAQ:XAIR) last posted its earnings results on Friday, June 26th. The company reported ($15.40) earnings per share for the quarter, missing the consensus estimate of ($11.33) by ($4.07). Beyond Air had a negative net margin of 432.99% and a negative return on equity of 350.00%. The firm had revenue of $1.91 million during the quarter, compared to analysts’ expectations of $2.30 million.

Beyond Air Stock Performance

NASDAQ XAIR traded up $0.16 on Tuesday, reaching $6.49. The stock had a trading volume of 32,236 shares, compared to its average volume of 169,593. The stock has a market cap of $4.67 million, a P/E ratio of -0.07 and a beta of 0.23. Beyond Air has a 12-month low of $5.02 and a 12-month high of $95.60. The business’s 50-day moving average price is $7.66 and its 200 day moving average price is $13.92. The company has a debt-to-equity ratio of 3.48, a quick ratio of 3.59 and a current ratio of 3.80.

Insiders Place Their Bets

In other news, CEO Robert Scott Goodman acquired 34,722 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were bought at an average cost of $5.76 per share, with a total value of $199,998.72. Following the purchase, the chief executive officer owned 34,822 shares of the company’s stock, valued at $200,574.72. This represents a 34,722.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 9.99% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in shares of Beyond Air by 57.5% in the fourth quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock valued at $49,000 after buying an additional 24,695 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Beyond Air during the 3rd quarter worth $1,753,000. Virtu Financial LLC purchased a new position in shares of Beyond Air in the 3rd quarter valued at about $48,000. Finally, Osaic Holdings Inc. grew its position in Beyond Air by 26.4% during the second quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after buying an additional 34,000 shares during the period. 31.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Beyond Air in a research note on Tuesday, July 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $200.00.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.